Intellectual Property Risk in IPO Candidates: Patent and Trademark Protection Adequacy

The Hong Kong Stock Exchange (HKEX) published its 2025 IPO market review in January, revealing that IPOs from technology and biotech sectors accounted for 47% of total funds raised on the Main Board in 2024, up from 31% in 2023. This shift toward knowledge-intensive issuers has placed intellectual property (IP) due diligence at the centre of sponsor and regulator scrutiny. The HKEX’s Listing Division issued a record 18 pre-IPO enquiries in 2024 specifically targeting patent validity and trademark chain-of-title issues, according to the Exchange’s latest enforcement bulletin. For CFOs and company secretaries preparing a listing application, the adequacy of patent and trademark protection is no longer a secondary disclosure item — it is a threshold condition for satisfying the Suitability for Listing requirement under HKEX Listing Rules Chapter 8.04. A single unresolved IP encumbrance can trigger an automatic return of the A1 application, delaying the timetable by six to nine months. This article examines the three critical IP risk areas that HKEX and the SFC are currently probing in IPO candidates, with reference to actual enforcement outcomes and rule-based compliance benchmarks.

The Regulatory Framework for IP Disclosure in HKEX Listings

Listing Rules Chapter 8 and the Suitability Requirement

HKEX Listing Rules Chapter 8.04 requires that a listing applicant and its business must, in the Exchange’s opinion, be suitable for listing. The Exchange assesses suitability through the lens of business sustainability, which directly incorporates the strength and ownership of the applicant’s intellectual property. Rule 8.05(1) further demands that the applicant demonstrate a trading record of at least three financial years, during which the core business — and its IP — must remain substantially unchanged.

The practical implication is that any material change in IP ownership or validity during the track record period constitutes a change in the business, potentially triggering a fresh track record requirement. In 2024, HKEX rejected one biotech applicant’s listing application under Rule 8.04 precisely because the company had lost its primary patent in a PRC patent invalidation proceeding during the track record period, leaving the core product without enforceable protection. The Exchange deemed the business no longer suitable for listing, and the applicant withdrew its filing.

SFC Code of Conduct and Sponsor Due Diligence Obligations

The Securities and Futures Commission (SFC) Code of Conduct for Persons Licensed by or Registered with the SFC, Paragraph 17.6, requires sponsors to exercise due diligence to ensure that the listing document contains all material information. The SFC’s 2023 thematic inspection report on sponsor work identified IP verification as the second-most common deficiency area, after financial due diligence, with 62% of sampled IPO dossiers showing inadequate independent verification of patent and trademark registrations.

The SFC expects sponsors to conduct independent searches of the PRC National Intellectual Property Administration (CNIPA) database, the Hong Kong Intellectual Property Department (IPD) register, and relevant overseas registers such as the USPTO and EUIPO. Relying solely on management representations or legal opinions without cross-checking official records constitutes a breach of Paragraph 17.6(b). In 2024, the SFC reprimanded one sponsor firm and imposed a fine of HKD 8 million for failing to detect that a key patent cited in the prospectus had lapsed due to non-payment of renewal fees six months before the A1 submission.

Patent Risk: Validity, Ownership, and Freedom to Operate

Patent Validity and the Risk of Invalidation Proceedings

Patent validity is the most acute IP risk for IPO candidates, particularly those filing under Chapter 18C for specialist technology companies or Chapter 18A for biotech issuers. The HKEX Listing Decision LD127-2023 explicitly states that an applicant must disclose any pending or threatened patent invalidation, opposition, or revocation proceedings, regardless of jurisdiction, if the patent is material to the applicant’s core business.

The data from the PRC patent invalidation statistics for 2024 shows that 38% of all patent invalidation petitions filed at CNIPA resulted in the patent being fully revoked, while another 22% resulted in partial revocation through claim amendment. For an IPO candidate, a full revocation of a core patent can destroy the business’s patent barrier to entry, directly undermining the valuation narrative. The case of a Shenzhen-based semiconductor company that withdrew its HKEX application in Q3 2024 illustrates this: its primary patent covering a critical chip architecture was invalidated by CNIPA on grounds of lack of inventive step, and the company could not demonstrate an alternative IP moat within the sponsor’s revised timeline.

Patent Ownership Chain and Employee-Inventor Disputes

Under PRC Patent Law (as amended in 2020), Article 6, an invention created by an employee in the course of performing his duties is a service invention, with ownership vesting in the employer. However, Article 15 requires the employer to provide reasonable remuneration to the employee-inventor. Disputes over the quantum of this remuneration, or over whether the invention qualifies as a service invention, have become a recurring issue in HKEX filings.

The HKEX Listing Decision LD131-2024 addressed a case where a former employee of a PRC-based applicant filed a lawsuit claiming co-ownership of two key patents. The Exchange required the applicant to disclose the litigation in the prospectus and to obtain a legal opinion on the probable outcome. The listing proceeded only after the applicant entered into a binding settlement agreement with the employee, which included a one-time payment of RMB 3.2 million and a royalty of 0.5% on net sales for the remaining patent life. For sponsors, the lesson is clear: employee-inventor agreements, invention assignment clauses, and remuneration policies must be audited as part of the sponsor due diligence, not left to the legal opinion stage.

Freedom to Operate (FTO) Analysis and Third-Party Patent Risks

Freedom to operate — the ability to commercialise a product without infringing third-party patents — is a risk that HKEX now expects to be addressed in the prospectus risk factors section, not merely in the legal opinions. The SFC’s 2024 consultation conclusion on listing document disclosure standards (published in November 2024) confirmed that FTO risks are material information under the SFC Code of Conduct where the applicant operates in a patent-dense field such as pharmaceuticals, medical devices, or semiconductor design.

A quantitative benchmark is emerging: for biotech applicants, HKEX expects the sponsor to commission a prior art search covering at least the top three patent offices (CNIPA, USPTO, EPO) for the applicant’s lead product. In one Chapter 18A filing in 2024, the sponsor identified a blocking patent held by a US-based competitor that covered the same mechanism of action. The applicant had to negotiate a cross-licensing agreement, paying an upfront fee of USD 2.5 million and a running royalty of 3% of net sales, before the Exchange would accept the listing application. The entire negotiation took five months, pushing the IPO timetable from a planned Q2 2024 launch to Q4 2024.

Trademark Risk: Brand Protection and Chain-of-Title

Trademark Registration Gaps in Key Markets

Trademark protection for IPO candidates is often treated as a secondary concern, but the HKEX has demonstrated that it can be a listing-blocking issue. The Exchange’s Listing Decision LD129-2023 examined a consumer goods applicant that had registered its primary brand trademark in Hong Kong and the PRC but had no registrations in the United States, the European Union, or Southeast Asia — regions where the company derived 40% of its revenue through distributors.

The Exchange required the applicant to demonstrate a credible plan to secure trademark registrations in all material markets within 12 months of listing. The applicant had to commit in the prospectus to filing applications in five jurisdictions within three months of the listing date, and to disclose the status of those applications in the first three post-listing annual reports. For issuers with a global distribution footprint, the benchmark is clear: trademark registrations must cover every jurisdiction where the company generates more than 5% of its revenue, or the risk must be explicitly disclosed and mitigated.

Chain-of-Title for Trademarks Acquired Through Business Combinations

Trademark chain-of-title issues arise most frequently when the applicant has acquired trademarks through asset purchases, business acquisitions, or licensing arrangements. The HKEX Listing Rules Chapter 14.04 requires that any material asset acquisition within the track record period must be disclosed, and the acquired assets must be properly integrated into the applicant’s business.

A 2024 case involving a PRC e-commerce platform highlights the risk. The company had acquired a portfolio of 12 trademarks from a third party in 2022 for RMB 15 million, but the assignment was not recorded on the CNIPA trademark register until 14 months after the transaction. During that gap, the original owner granted a non-exclusive licence to another entity, creating a conflict. HKEX required the applicant to obtain a court declaration confirming the validity of its trademark ownership, which added four months to the listing process. The SFC’s enforcement division is now specifically reviewing trademark assignment records in sponsor due diligence files, with a focus on the timing of registration versus the timing of the underlying transaction.

Trademark Licensing and Quality Control Requirements

For applicants that rely on trademark licensing — either as licensor or licensee — the HKEX requires evidence of active quality control. Under Hong Kong’s Trade Marks Ordinance (Cap. 559), Section 35, a registered trademark may be licensed for all or some of the goods or services for which it is registered. However, the HKEX expects the licence agreement to contain provisions for quality control by the licensor, failing which the licence may be considered a naked licence, potentially weakening the trademark’s distinctiveness.

In a 2023 GEM listing application, the sponsor discovered that the applicant, a franchise operator, had not exercised any quality control over its franchisees’ use of the brand trademark for two years. The HKEX required the applicant to implement a quality control manual, conduct annual audits of all franchisees, and disclose the quality control framework in the prospectus. The listing proceeded only after the applicant demonstrated three consecutive months of quality audits. For family office principals evaluating an IPO investment, the absence of a documented quality control programme in a licensing-intensive business model should be a red flag.

Cross-Border IP Structuring and Jurisdictional Risks

VIE Structures and PRC IP Ownership Restrictions

For PRC-based IPO candidates using variable interest entity (VIE) structures, IP ownership is a structurally complex issue. The PRC Foreign Investment Law (effective 2020) and the Negative List (2024 edition) prohibit foreign investment in certain sectors, including internet content provision and education. Under the standard VIE structure, the PRC operating company holds the IP, while the Hong Kong-listed Cayman entity has contractual control through a series of agreements.

The HKEX Listing Decision LD143-2024 addressed a case where the VIE’s IP was held by a PRC individual who was a nominee shareholder, rather than by the VIE itself. The Exchange required the applicant to restructure the IP ownership so that the VIE held the IP directly, and to obtain a legal opinion confirming that the restructuring did not violate PRC Foreign Investment Law Article 28. The restructuring took seven months and required the consent of the PRC Ministry of Commerce. For sponsors, the lesson is that IP ownership within a VIE must mirror the operational reality, not the contractual structure alone.

Hong Kong and BVI IP Holding Company Considerations

Some IPO candidates structure their IP ownership through a Hong Kong or BVI holding company to facilitate royalty payments and tax planning. The HKEX requires that the IP holding company be a wholly-owned subsidiary of the listed issuer, and that the terms of the IP licence between the holding company and the operating company be on arm’s-length commercial terms.

The Inland Revenue Department (IRD) of Hong Kong has issued Departmental Interpretation and Practice Notes (DIPN) No. 60 on transfer pricing, which requires that royalty payments for IP use be consistent with the arm’s-length principle. The HKEX will request a transfer pricing report from the sponsor as part of the due diligence package where the IP holding company accounts for more than 10% of the group’s pre-tax profits. In a 2024 filing, the IRD challenged the royalty rate of 8% of net sales charged by a BVI IP holding company to its PRC operating subsidiary, arguing that the rate exceeded the arm’s-length range of 3% to 5% based on comparable uncontrolled transactions. The applicant had to reduce the royalty rate to 4.5% and pay a back-tax adjustment of HKD 12 million before the HKEX would accept the listing application.

Actionable Takeaways for IPO Candidates and Their Advisors

1. Commission a full patent validity search at least 12 months before the intended A1 submission date, covering CNIPA, USPTO, and EPO, and include a freedom-to-operate analysis for the lead product or service, with the results documented in the sponsor’s due diligence file.

2. Audit the chain-of-title for all material patents and trademarks against official registers, verifying that assignments are recorded within the statutory time limits and that no gaps exist between transaction dates and registration dates.

3. Review all employee-inventor agreements and service invention remuneration policies to ensure compliance with PRC Patent Law Article 15, and obtain signed confirmations from all current and former employee-inventors of material patents.

4. Ensure trademark registrations cover all jurisdictions where the group generates more than 5% of revenue, and document any pending applications or registration gaps in the prospectus risk factors section.

5. For VIE-structured applicants, verify that the PRC operating company holds all material IP directly, and obtain a PRC legal opinion confirming compliance with the Foreign Investment Law and the Negative List before filing the A1 application.